The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19
Open accessAbstract
In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coronavirus disease (COVID-19) pandemic.
Rampal, L., & Liew, B. S. (2020) · PubMed · Cited by 2,115
Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020) · Aging and Disease · doi:10.14336/ad.2020.0228 · Cited by 1,153
Kalil, A. C. (2020) · JAMA · doi:10.1001/jama.2020.4742 · Cited by 501
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
Turner, L., & Knoepfler, P. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.06.007 · Cited by 349
Self-citationLiang, B., Chen, J., Li, T., Wu, H., Yang, W., Li, Y., Li, J., Yu, C., Nie, F., Ma, Z., et al. (2020) · Medicine · doi:10.1097/md.0000000000021429 · Cited by 328
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19
Khoury, M., Cuenca, J., Cruz, F. F., Figueroa, F. E., Rocco, P. R. M., & Weiss, D. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00858-2020 · Cited by 244
Manchikanti, L. (2020) · Pain Physician · doi:10.36076/ppj.2020/23/e71 · Cited by 224
Marketing of unproven stem cell–based interventions: A call to action
Sipp, D., Caulfield, T., Kaye, J. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0426 · Cited by 202
Caulfield, T., Sipp, D., Murry, C. E., Daley, G. Q., & Kimmelman, J. (2016) · Science · doi:10.1126/science.aaf4620 · Cited by 134
Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential
Khoury, M., Rocco, P. R. M., Phinney, D. G., Krampera, M., Martín, I., Viswanathan, S., Nolta, J. A., LeBlanc, K., Galipeau, J., & Weiss, D. J. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.089 · Cited by 44
Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions
Horner, C., Tenenbaum, E. M., Sipp, D., et al. (2018) · npj Regenerative Medicine · doi:10.1038/s41536-018-0043-6 · Cited by 42
Flagged first, then by citations
Research works printed but not linked: 1
- Khoury, 2020, Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential, Cytotherapy
Cited by
Sorted by citations
Human Germline and Heritable Genome Editing: The Global Policy Landscape
Baylis, F., Darnovsky, M., Hasson, K., & Krahn, T. M. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0082 · Cited by 155
“Patterns of transnational exploitation have been observed with the marketing of recent biotechnolo-gies such as unproven ‘‘stem cell therapies’’ 58,59 and human nuclear genome transfer.”
Metadata
- Authors
- Turner, L.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Turner, Leigh
- ORCID
- Turner, Leigh
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 26
- Issue
- 6
- Pages
- 806-810
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- PMC
- PMC7203029
- OpenAlex
- W3023611938
- Cited by
- 46
- References
- 11
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 14 · 2020: 12
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell stem cell (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Society for Stem Cell Research
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Social Sciences › Sociology and Political Science › Misinformation and Its Impacts
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Keywords
- stem cell therapy, COVID-19 pandemic, unproven treatments, deceptive marketing, public health emergencies, consumer fear, stem cell therapy regulation
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Commerce, Fear, Humans, Pneumonia, Viral, Coronavirus Infections, Stem Cell Transplantation, Marketing, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
